Q1 Net Loss Improves, $13.9M Public Offering Completed, and Authorized Shares Corrected to 2 Billion

summarizeSummary

PLUS THERAPEUTICS, INC. reported improved Q1 net loss, completed a $13.9 million public offering, repaid a $4.5 million investor liability, and corrected its authorized shares to 2 billion, while still facing a 'going concern' warning.

check_boxKey Events

• Q1 Net Loss Significantly Reduced

  The company reported a net loss of $6.9 million for the first quarter of 2026, a substantial improvement from the $17.4 million net loss in Q1 2025, largely due to lower non-cash financing expenses.

• Successful $13.9M Public Offering

  In January 2026, the company completed an underwritten public offering, raising approximately $13.9 million in net proceeds, which is critical for its liquidity and operations.

• Working Capital Boost and Debt Repayment

  Working capital increased to $10.1 million as of March 31, 2026, from $2.9 million at December 31, 2025. The company also repaid a $4.5 million investor liability, leading to the cancellation of 272,821 shares.

• Authorized Shares Corrected to 2 Billion

  A Certificate of Correction filed on May 12, 2026, clarified that the total authorized common stock is 2 billion shares, not 200 million, providing extensive flexibility for future equity raises.

auto_awesomeAnalysis

PLUS THERAPEUTICS, INC. reported a significantly reduced net loss of $6.9 million for Q1 2026, compared to $17.4 million in Q1 2025, primarily due to the absence of large non-cash financing expenses and derivative fair value changes seen in the prior year. The company successfully completed a public offering in January 2026, raising $13.9 million in net proceeds, which is crucial given its ongoing cash burn and 'going concern' warning. Working capital improved substantially to $10.1 million from $2.9 million at year-end 2025. The company also repaid a $4.5 million investor liability and regained Nasdaq bid price compliance following a 1-for-25 reverse stock split. A subsequent filing corrected the authorized common stock from 200 million to 2 billion shares, providing significant headroom for future capital raises but also indicating substantial potential for dilution.